Sero-Prevalence of HBV, HCV and HEV among the Egyptian Pregnant Females

Elsharkawy, Suzan; Elgazayerli, Wael Samir

doi:10.4236/ojog.2019.910138

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The seroprevalence of HEV‐IgG among Egyptian pregnant women is 18.4%–84.3% 201–205 (Figure 3e). The risk factors of HEV infection among Egyptian pregnant women included rural residence, age over 30 years, being in the third trimester, multiple pregnancies, frequent contact with cats, and poor sanitation 204,205 …”

Section: Hepatitis E Virusmentioning

confidence: 99%

Current situation of viral hepatitis in Egypt

Elbahrawy

Ibrahim

Eliwa

et al. 2021

Microbiology and Immunology

View full text Add to dashboard Cite

An estimated 8–10 million people suffer from viral hepatitis in Egypt. Hepatitis A virus (HAV) and hepatitis E virus (HEV) are the major causes of viral hepatitis in Egypt as 50% or more of the Egyptian population are already exposed to HAV infection by the age of 15. In addition, over 60% of the Egyptian population test seropositive for anti‐HEV in the first decade of life. HEV mainly causes self‐limiting hepatitis; however, cases of fulminant hepatitis and liver failure were reported in Egypt. Hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV) are the main causes of chronic hepatitis, liver cirrhosis, and liver cancer (hepatocellular carcinoma [HCC]) in Egypt. Globally, Egypt had the highest age‐standardized death rate due to cirrhosis from 1990 to 2017. The prevalence rate of HBV (1.3%–1.5%) has declined after national infantile immunization. Coinfection of HBV patients with HDV is common in Egypt because HDV antibodies (IgG) vary in range from 8.3% to 43% among total HBV patients. After the conduction of multiple national programs to control HCV infection, a lower rate of HCV prevalence (4.6%) was recently reported. Data about the incidence of HCV after treatment with direct antiviral agents (DAAs) are lacking. An HCC incidence of 29/1000/year in cirrhotic patients after DAA treatment is reported. A higher rate of infiltrative pattern among HCC patients after DAA treatment is also recognized. Viral hepatitis is one of the major public health concerns in Egypt that needs more attention and funding from health policymakers.

show abstract

Section: Hepatitis E Virusmentioning

confidence: 99%

Current situation of viral hepatitis in Egypt

Elbahrawy

Ibrahim

Eliwa

et al. 2021

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…Treg/Th17 can reflect the state of immune function [13,14] . In this study, the levels of Th cytokines INF-γ, IL-2, IL-4, IL-6 and Treg/Th17 ratio were detected.…”

Section: Resultsmentioning

confidence: 99%

Clinical Characteristics of Hepatitis in Pregnancy in Pregnant Women with Chronic Hepatitis B Virus Infection and Evaluation of the Efficacy of Antiviral Therapy

Li¹,

Bi²

2021

ijps

View full text Add to dashboard Cite

Li et al.: Efficacy of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B Virus InfectionTo explore the clinical characteristics of hepatitis in pregnant women with chronic hepatitis B virus infection and the efficacy of telbivudine treatment is the main objective. In this study, 136 pregnant women with hepatitis B virus infection diagnosed in our hospital from March 2017 to December 2018 were selected as the research objects. According to whether the patients had hepatitis episodes, they were divided into 96 cases in the seizure group and 40 cases in the non-seizure group. The two groups of patients were compared. The difference of serum alanine aminotransferase, aspartate aminotransferase, hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen; randomize the attack group of patients and divide into telbivudine group and entecavir group with 48 cases each. Compare hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen, serum alanine aminotransferase, aspartate aminotransferase changes at different times before and after treatment and peripheral blood T helper cell factors and regulatory T cells/T helper 17 cells levels changes and shows differences in neonatal outcomes. The hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen, serum alanine aminotransferase and aspartate aminotransferase levels of the hepatitis attack group were higher than those of the non-seizure group and the difference was statistically significant (p<0.05). The age of the patients in the hepatitis attack group was mainly concentrated in the range of 22-28 y (56.25 %), onset time is mainly concentrated in 13-24 w (87.50 %), hepatitis B virus-deoxyribonucleic acid level is mainly ≥6 log10IU/ml (78.13 %), hepatitis B surface antigen ≥4 log10IU/ml (55.21 %), hepatitis B e antigen ≥2 log10S/CO (70.83 %). Before treatment, there was no significant difference in hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen, serum alanine aminotransferase and aspartate aminotransferase levels between the telbivudine group and the entecavir group (p>0.05), after 12 w of treatment, the hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen, serum alanine aminotransferase and aspartate aminotransferase levels were not statistically significant (p>0.05). The levels of hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen, serum alanine aminotransferase and aspartate aminotransferase in the telbivudine group were lower than those in the entecavir group and the difference was statistically significant (p<0.05). Before treatment, the interferon gamma and interleukin-2 levels of the telbivudine group and the entecavir group were compared with Interleukin-4, Interleukin-6 and regulatory T cells/T helper 17 cells, the difference was not statistically significant (p>0.05). After 12 w of treatment, the leve...

show abstract

Seroprevalence of hepatitis B virus surface antigen (HBsAg) in Egypt (2000–2022): a systematic review with meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background Hepatitis B infection seriously threatens global public health, especially in developing nations. Despite several investigations on HBV incidence, the national pooled prevalence remains unknown, particularly in populations at-risk at whom interventions should be primarily aimed. Methods A comprehensive literature search of the following databases: Medline [PubMed], Scopus, Google Scholar, and Web of Science was conducted following the PRISMA guidelines. I-squared and Cochran's Q were used to measure the heterogeneity between the studies. Publications that matched the following were included: Primary studies published in Egypt from 2000 to 2022 reported HBV prevalence based on HBsAg. We excluded any studies that were not performed on Egyptians or that were performed on patients suspected of acute viral hepatitis or studies focusing on occult hepatitis or vaccination evaluation studies, or national surveys. Results The systematic review included 68 eligible studies reporting a total of 82 incidences of HBV infection based on hepatitis B surface antigen with a total sample size of 862,037. The pooled national prevalence among studies was estimated to be 3.67% [95% CI; 3: 4.39]. Children under 20 with a history of HBV vaccination during infancy had the lowest prevalence of 0.69%. The pooled prevalence of HBV infection among pregnant women, blood donors, and healthcare workers was 2.95%, 1.8%, and 1.1%, respectively. While patients with hemolytic anemia and hemodialysis patients, patients with malignancies, HCC patients, and chronic liver disease patients had the highest prevalences at 6.34%, 25.5%, 18.6%, and 34%, respectively. Studies reporting HBV prevalence in urban settings compared to rural settings revealed a similar HBV prevalence of 2.43% and 2.15%, respectively. Studies comparing HBV prevalence in males and females revealed a higher prevalence among males (3.75%) than females (2.2%). Conclusion In Egypt, hepatitis B infection is a significant public health issue. The blocking of mother-to-infant hepatitis B transmission, the scaling up of the scope of the existing vaccination program, and implementing new strategies, including screen-and-treat, may reduce the prevalence of the disease.

show abstract

Sero-Prevalence of HBV, HCV and HEV among the Egyptian Pregnant Females

Cited by 3 publications

References 27 publications

Current situation of viral hepatitis in Egypt

Current situation of viral hepatitis in Egypt

Clinical Characteristics of Hepatitis in Pregnancy in Pregnant Women with Chronic Hepatitis B Virus Infection and Evaluation of the Efficacy of Antiviral Therapy

Seroprevalence of hepatitis B virus surface antigen (HBsAg) in Egypt (2000–2022): a systematic review with meta-analysis

Contact Info

Product

Resources

About